Cor Vasa 2009, 51(2):97-102 | DOI: 10.33678/cor.2009.026

Heart-rate slowing drugs in the treatment of myocardial infarction survivors

Jiří Vítovec1,*, Jindřich ©pinar2
1 I. interní kardioangiologická klinika, Fakultní nemocnice u sv. Anny v Brně a Lékařská fakulta Masarykovy univerzity
2 Fakultní nemocnice Brno a Lékařská fakulta Masarykovy univerzity, Brno, Česká republika

The authors present a review of heart rate-slowing drugs given to myocardial infarction survivors, including digoxin as an inotrope, beta-blockers reducing sympathetic activity, calcium-channel blockers such as verapamil, diltiazem with their vasodilator action, and the sinus node inhibitor ivabradine, which is currently undergoing clinical trials. The article discusses current concepts and lists indications for their use in secondary prevention in patients after myocardial infarction.

Keywords: Heart rate; Digoxin; Beta-blockers; Verapamil; Diltiazem; Ivabradine; Secondary prevention after myocardial infarction

Published: February 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, ©pinar J. Heart-rate slowing drugs in the treatment of myocardial infarction survivors. Cor Vasa. 2009;51(2):97-102. doi: 10.33678/cor.2009.026.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J 1987;113:1489-94. Go to original source... Go to PubMed...
    2. Hjalmarson A, Gilpin EA, Kjekshus J, et al. Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol 1990;65:547-53. Go to original source... Go to PubMed...
    3. Stangeland L, Grong K, Vik-Mo H, et al. Is reduced cardiac performance the only mechanism for myocardial infarct size reduction during beta adrenergic blockade? Cardiovasc Res 1986;20:322-30. Go to original source... Go to PubMed...
    4. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986;57:43F-49F. Go to original source... Go to PubMed...
    5. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J 2007;28:3012-9. Go to original source... Go to PubMed...
    6. Hradec J. Selektivní ovlivnění srdeční frekvence - nový fenomén v kardiovaskulární farmakoterapii. Remedia 2008;18:114-9.
    7. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999;99:1265-70. Go to original source... Go to PubMed...
    8. Herrick JB. Clinical features of sudden obstruction of the coronary arteries. JAMA 1912;49:2015-22. Go to original source...
    9. Karliner JS, Braunwald E. Present status of digitalis treatment of acute myocardial infarction. Circulation 1972;45:891-902. Go to original source... Go to PubMed...
    10. Morrison J, Coromilas J, Robbins M, et al. Digitalis and myocardial infarction in man. Circulation 1980;62:8-16. Go to original source... Go to PubMed...
    11. Moss AJ, Davis HT, Conard DL, et al. Digitalis-associated cardiac mortality after myocardial infarction. Circulation 1981;64:1150-6. Go to original source... Go to PubMed...
    12. Yusuf S, Wittes J, Bailey K, Furberg C. Digitalis - a new controversy regarding an old drug. The pitfalls of inappropriate methods. Circulation 1986;73:14-8. Go to original source... Go to PubMed...
    13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33. Go to original source... Go to PubMed...
    14. Gheorghiade M, van Veldhuisen DJ, Colucci WS. Contemporary use of digoxin in the management of cardiovascular disorders. Circulation 2006; 113:2556-64. Go to original source... Go to PubMed...
    15. Opie LH, Poole-Wilson PA. Beta-Blocking Agents. In: Opie LH, Gersh BJ. Drugs for the Heart. 6th ed. Chybí město: Elsevier Saunders, 2005:1-32.
    16. Snow PJD. Effect of propranol in myocardial infarction. Lancet 1965;2:551-3. Go to original source... Go to PubMed...
    17. Norwegian Multicenter Study Group Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction N Engl J Med 1981;304:801-7.
    18. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarctionI. Mortality results. JAMA 1982;247:1707-14. Go to original source...
    19. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction arrhythmias. Am J Cardiol 1985;56:35G-38G.
    20. Freemantle N, Cleland J, Young P, et al. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. Br Med J 1999; 318:1730-7. Go to original source... Go to PubMed...
    21. COMMIT/CCS-2: Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1622-32.
    22. The CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricular dysfunction. The CAPRICORN randomised trial. Lancet 2001;357:1385-90. Go to original source... Go to PubMed...
    23. First International Study of Infarct Survival Collaborative Group Mechanisms for the early mortality reduction produced by beta-blockade started early in acute myocardial infarction: ISIS-1. Lancet 1988;343:921-32.
    24. Widimský J. Farmakoterapie ischemické choroby srdeční. Praha: Grada Publishing, 1997:259.
    25. Task Force Members: Expert consensus document on beta-adrenergic receptor blockers: The Task Force on Beta-Blockers of the European Society of Cardiology. Eur Heart J 2004; 25:1341-62. Go to original source... Go to PubMed...
    26. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92. Go to original source... Go to PubMed...
    27. Goldstein RE, Boccuzzi SJ, Cruess D, Nattel S. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation 1991;83:52-60. Go to original source... Go to PubMed...
    28. The Danish Verapamil Infarction Trial II-DAVIT II. Effect of verapamil on mortality major events after acute myocardial infarction. Am J Cardiol 1990; 66:779-85. Go to original source... Go to PubMed...
    29. Rengo F, Carbonin P, Pahor M, et al. A controlled trial of verapamil in patients after acute myocardial infarction: results of the calcium antagonist reinfarction Italian study (CRIS). Am J Cardiol 1996;77:365-9. Go to original source... Go to PubMed...
    30. Bultas J. Ivabradin. Remedia 2006;16:463-73. Go to original source...
    31. Fox K, Ford I, Steg PG, et al. Ivabradine for patiens with stable coronary artery disease and lef-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008:372: 807-16. Go to original source... Go to PubMed...
    32. Fox K, Ford I, Steg PG, et al. Heart rate as a prognostic risk factor in patiens with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomized controlled trial. Lancet 2008;372:817-21. Go to original source... Go to PubMed...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes